Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
  • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H1/00—Processes for the preparation of sugar derivatives
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Definitions

• the present disclosure relates to separation and purification of nucleic acids from paraffin-containing samples. More specifically, the disclosure relates to the separation and purification of nucleic acids from formalin-fixed paraffin-embedded (FFPE) tissue samples.
• FFPE formalin-fixed paraffin-embedded
• Genotyping and gene expression analyses of tissue samples can be of significant importance for the identification of disease biomarkers (e.g., genetic determinants), for the accurate diagnosis of disease, and for the determination of patients' course of treatment.
• Pharmacogenomic methods can identify patients likely to respond to a particular drug and lead to new therapeutic approaches. For example, tumor tissue excised from a patient can be analyzed for the increased or decreased expression of particular disease biomarkers and thereby help clinicians identify therapeutic agents that could be useful in treating the patient.
• Genotyping and gene expression studies e.g., by reverse transcriptase polymerase chain reaction (RT-PCR) amplification
• RT-PCR reverse transcriptase polymerase chain reaction
• pathological samples are not prepared as frozen tissues, but rather are formalin-fixed and paraffin-embedded (FFPE) to allow histological analysis and archival storage.
• FFPE formalin-fixed and paraffin-embedded
• separating ribonucleic acid from a paraffin-containing sample that involve: (a) heating the sample at about 50-85 0 C for about 1-60 minutes in the presence of an ionic detergent to produce a paraffin phase and an aqueous phase; (b) removing the aqueous phase from the paraffin phase; and (c) adding a protease to the aqueous phase and incubating the aqueous phase at about 25-8O 0 C for about 5-60 minutes.
• the paraffin-containing sample is a formalin fixed paraffin embedded (FFPE) tissue sample.
• the heating is between about 64-85 0 C. In some embodiments, the heating is between about 60-75 0 C.
• the heating is at about 72 0 C. In some embodiments, the heating is for about 1-30 min. In some embodiments, the heating is for about 10 min.
• the ionic detergent is sodium dodecylsulfate (SDS), or Sarcosine.
• the protease is Proteinase K.
• the incubating is at about 35-7O 0 C. In some embodiments, the incubating is at about 55-65 0 C. In some embodiments, the incubating is at about 56-58 0 C. In some embodiments, the incubating is for about 5-30 min. In some embodiments, the incubating is for about 10 min.
• the methods further involve purifying the ribonucleic acid from the aqueous phase.
• the purifying involves TRIZOL precipitation, guanidinium isothiocyanate, anion exchange chromatography, silica- based purification, ChargeSwitch® purification, or nucleic acid hybridization.
• Also provided are methods for separating ribonucleic acid from a paraffin-containing sample that involve: (a) heating the sample at about 50-85 0 C for about 1-60 minutes in the presence of an ionic detergent to produce a paraffin phase and an aqueous phase; and (b) adding a protease to the aqueous phase and incubating the aqueous phase at about 25- 8O 0 C for about 5-60 minutes.
• the methods further involve removing the aqueous phase from the paraffin phase.
• the paraffin-containing sample is a formalin fixed paraffin embedded (FFPE) tissue sample.
• the heating is between about 64 0 C and about 85 0 C.
• the heating is at about 60-75 0 C. In some embodiments, the heating is at about 72 0 C. In some embodiments, the heating is for about 1-30 min. In some embodiments, the heating is for about 10 min.
• the ionic detergent is SDS or Sarcosine.
• the protease is Proteinase K.
• the incubating is at about 35-7O 0 C. In some embodiments, the incubating is at about 55-65 0 C. In some embodiments, the incubating is at about 56-58 0 C. In some embodiments, the incubating is for about 5-30 min. In some embodiments, the incubating is for about 10 min.
• the methods further involve purifying the ribonucleic acid from the aqueous phase.
• the purifying involves TRIZOL precipitation, guanidinium isothiocyanate, anion exchange chromatography, silica-based purification, ChargeSwitch® purification, or nucleic acid hybridization.
• methods for separating ribonucleic acid from a paraffin-containing sample that involve heating the sample to about 50-85 0 C for about 1-60 minutes in the presence of an ionic detergent and a protease to produce a paraffin phase and an aqueous phase.
• the methods further involve removing the aqueous phase from the paraffin phase.
• the paraffin-containing sample is a formalin fixed paraffin embedded (FFPE) tissue sample.
• the heating is at about 64- 85 0 C. In some embodiments, the heating is at about 60-75 0 C. In some embodiments, the heating is at about 65 0 C. In some embodiments, the heating is for about 1 min to about 30 min. In some embodiments, the heating is for about 10 min.
• the ionic detergent is SDS or Sarcosine.
• the protease is Proteinase K.
• the methods further involve purifying the ribonucleic acid from the aqueous phase. In some embodiments, the purifying involves TRIZOL precipitation, guanidinium isothiocyanate, anion exchange chromatography, silica-based purification, ChargeSwitch® purification, or nucleic acid hybridization.
• Also provided are methods for separating deoxyribonucleic acid from a paraffin- containing sample that involve: (a) heating the sample at about 75-100 0 C for about 1-60 minutes in the presence of a detergent to produce a paraffin phase and an aqueous phase; (b) removing the aqueous phase from the paraffin phase; and (c) adding a protease to the aqueous phase and incubating the aqueous phase at about 25-8O 0 C for about 5-60 minutes.
• the paraffin-containing sample is a formalin-fixed paraffin embedded (FFPE) sample.
• the heating is at about 85-100 0 C. In some embodiments, the heating is at about 100 0 C.
• the heating is for about 1-30 min. In some embodiments, the heating is for about 10 min.
• the detergent is an ionic detergent. In some embodiments, the ionic detergent is sodium dodecyl sulfate (SDS) or Sarcosine. In some embodiments, the detergent is a non-ionic detergent. In some embodiments, the non-ionic detergent is Triton X-114, NP-40 or Tween-20. In some embodiments, the protease is Proteinase K. In some embodiments, the incubating is at about 35-7O 0 C. In some embodiments, the incubating is at about 55-65 0 C. In some embodiments, the incubating is at about 62 0 C.
• the incubating is for about 5-30 min. In some embodiments, the incubating is for about 10 min. In some embodiments, the methods further involve purifying the deoxyribonucleic acid from the aqueous phase. In some embodiments, the purifying involves TRIZOL precipitation, guanidinium isothiocyanate, anion exchange chromatography, silica-based purification, ChargeSwitch® purification, or nucleic acid hybridization.
• Also provided are methods for separating deoxyribonucleic acid from a paraffin- containing sample that involve: (a) heating the sample to about 75-100 0 C for about 1-60 minutes in the presence of a detergent to produce a paraffin phase and an aqueous phase; and (b) adding a protease to the aqueous phase and incubating the aqueous phase at about 75- 100 0 C for 5-60 minutes.
• the paraffin-containing sample is a formalin- fixed paraffin embedded (FFPE) sample.
• the heating is at about 85- 100 0 C. In some embodiments, the heating is at about 100 0 C. In some embodiments, the heating is for about 1-30 min.
• the heating is for about 10 min.
• the detergent is an ionic detergent.
• the ionic detergent is sodium dodecyl sulfate (SDS) or Sarcosine.
• the detergent is a non-ionic detergent.
• the non-ionic detergent is Triton X-114, NP- 40 or Tween-20.
• the protease is Proteinase K.
• the incubating is at about 35-7O 0 C 1 In some embodiments, the incubating is at about 55-65 0 C. In some embodiments, the incubating is at about 62 0 C.
• the incubating is for about 5-30 min. In some embodiments, the incubating is for about 10 min. In some embodiments, the methods further involve the deoxyribonucleic acid from the aqueous phase. In some embodiments, the purifying involves TRIZOL precipitation, guanidinium isothiocyanate, anion exchange chromatography, silica-based purification, ChargeSwitch® purification, or nucleic acid hybridization.
• Methods of the invention may be used for separating and purifying nucleic acid from any paraffin-containing sample, including preserved (e.g., with formalin) tissue samples.
• Paraffin-containing samples may include tissue from any organism: vertebrate (e.g., mammals such as humans, primates, canines, felines, porcines, equines and bovines, as non-mammals such as birds, fish, amphibians and reptiles) or invertebrate (e.g., insects).
• normal and diseased (e.g., tumor) tissue may be processed using the disclosed methods.
• Tumor types include those derived from skin, prostate, ovary, uterus, breast, lung, pancreas, small intestine, colon, liver, kidney, and brain.
• Methods of the invention may be used for separating and purifying any nucleic acid, the quality of which is suitable for genetic manipulation (e.g., cloning, amplification, sequencing, RT-PCR and cDNA library construction), genotyping, and gene expression studies.
• Single stranded (ss) DNA, ssRNA (e.g., micro-RNA), double stranded (ds) DNA, and ds RNA may be separated and purified from paraffin-containing samples using the disclosed methods.
• the target nucleic acid may be linear or circular, and may be total RNA, niRNA, and chromosomal or genomic DNA (gDNA).
• Methods of the invention generally involve a melting step, where paraffin-containing tissue samples are heated in the presence of a detergent, causing the paraffin to melt and tissue sample cells to lyse. From the resulting two-phase mixture (i.e., a paraffin phase and an aqueous phase), the aqueous phase is collected for purification of nucleic acid.
• Protease(s) can be used at one or more points in the separation process to facilitate tissue cell lysis and/or degrade proteins that could degrade nucleic acid or interfere with subsequent genetic manipulation or analysis.
• a protease can be included before or during the melting step, and/or can be added to the aqueous phase of the two-phase mixture either before or after it is collected from the paraffin phase.
• a paraffin-containing sample is heated in the presence of a detergent, causing the paraffin to melt and tissue sample cells to lyse.
• a paraffin-containing sample is heated at about 5O 0 C to 85 0 C.
• the sample is heated at about 64 0 C to 85 0 C, or at about 6O 0 C to 75 0 C.
• the sample is heated at about 72 0 C.
• DNA e.g., gDNA
• a paraffin-containing sample is heated at about 75 0 C to 100 0 C.
• the sample is heated at about 85 0 C to 100 0 C. In one DNA-separation embodiment, the sample is heated at about 100 0 C.
• the melting step generally is performed for 1 to 60 minutes. In some embodiments, a paraffin-containing sample is heated for 1 to 30 minutes, or for 5 to 20 minutes. In one embodiment, the melting step is performed for about 10 min.
• the melting step is performed in the presence of a detergent-containing buffer that facilitates cell lysis.
• the detergent-containing buffer may include one or more ionic and/or one or more non-ionic detergents.
• Suitable ionic detergents include sodium dodecyl sulfate (SDS), lauroylsarcosine, Na+ salt ("sarcosine" or Sarkosyl), bile salt detergents (e.g., CHAPS, CHAPSO, sodium deoxycholate, sodium taurocholate, sodium glychocholate, sodium glychodeoxycholate) and cetyltrimethylammonium bromide (CTAB).
• SDS sodium dodecyl sulfate
• lauroylsarcosine Na+ salt
• bile salt detergents e.g., CHAPS, CHAPSO, sodium deoxycholate, sodium taurocholate, sodium glychocholate, sodium glychodeoxycholate
• CTAB cetyltrimethyl
• Nonionic detergents include sarcosine, Tween-20, NP-40, Triton X-IOO, NP-10, Triton X-114, Tween- 80 and r ⁇ -octanoyl- ⁇ -D-glucosylamine (NOGA).
• the detergent-containing buffer may also include a buffer salt such as Tris- HCl (pH 7.5-8.5), phosphates, HEPES, PIPES, MOPS, MES, TABS, TRICINE, NaCl, KCl, MgCl 2 , a chelating agent (e.g., EDTA or EGTA), and/or a preservative.
• a buffer salt such as Tris- HCl (pH 7.5-8.5), phosphates, HEPES, PIPES, MOPS, MES, TABS, TRICINE, NaCl, KCl, MgCl 2 , a chelating agent (e.g., EDTA or
• Ionic and/or non-ionic detergents can be used for separation of RNA. In some embodiments, ionic detergents are used for separation of RNA. Ionic and/or non-ionic detergents can be used for separation of DNA. In some embodiments, non-ionic detergents are used for separation of DNA.
• the melting step causes the paraffin to melt and tissue sample cells to lyse.
• the aqueous phase is collected for purification of nucleic acid.
• Centrifugation can be used to facilitate separation of the paraffin and aqueous phases.
• samples can be centrifuged at room temperature (or lower) at a suitable speed (e.g., maximal speed on a microcentrifuge) to facilitate separation of the paraffin phase from the nucleic acid-containing aqueous phase.
• the paraffin may solidify to form a layer above the aqueous phase.
• a pipette tip can be used to penetrate the paraffin layer to remove the aqueous phase.
• Nucleic acids can be purified from the collected aqueous phase using any known method, including those that involve TRIZOL precipitation, ethanol precipitation, guanidinium isothiocyanate treatment, phenol-chloroform treatment, chromatography (e.g., anion exchange chromatography), silica-based purification, ChargeSwitch® purification (see PCT WO 99/29703 and PCT WO02/48164), nucleic acid hybridization, column chromatography, or magnetic bead based purification.
• Target RNA may be treated with DNase ⁇ e.g. DNase I) to degrade contaminating DNA.
• Target DNA may be treated with RNase (e.g. RNase I) to degrade contaminating RNA.
• Protease(s) can be used at one or more points in the separation process to facilitate tissue cell lysis and/or degrade proteins that could degrade the target nucleic acid or interfere with its subsequent manipulation or analysis.
• protease(s) can be included before or during the melting step (e.g., as a component of the detergent-containing buffer).
• Protease(s) also can be added to the aqueous phase of the two-phase mixture that results from the melting step, either before or after it is collected from the paraffin phase.
• Aqueous phase nucleic acids also can be applied to a substrate (e.g., affinity column) and subjected to protease treatment while associated with the substrate.
• any protease can be used for the separation methods described herein.
• a proteases of a thermophilic bacterium such as ⁇ zermus Aquaticus, Thermus filiformis, Thermotoga neapolitana, Thermotoga maritime and Thermococcus z ⁇ lligi, (e.g., Thermus sp, strain RT41a thermostable alkaline protease (Peek et al., Eur, J. Biochem, 207:1035-1044, 1992) and EAl protease (Moss et al., Int. J. Legal Med. 117:340-349, 2003)) is used.
• Proteinase K is used.
• the protease can be incubated in the aqueous phase (either before or after it is collected from the paraffin phase) at about 25 0 C to 8O 0 C (e.g., about 35 0 C to 7O 0 C, about 5O 0 C to 7O 0 C, about 55 0 C to 65 0 C, about 55 0 C to 6O 0 C, about 6O 0 C to 65 0 C, about 56 0 C to 58 0 C, or about 62 0 C).
• Such protease digestion generally is performed for about 5-30 minutes (e.g,, about 10-20 minutes, or about 10 minutes).
• Proteinase K digestion is performed for about 10 min at a temperature between 56 0 C and 58 0 C.
• Protease treatment may be performed in the presence of a chelating agent (e.g., EDTA or EGTA) present at about 1 to 500 niM (e.g., about 1 to 100 mM).
• a chelating agent e.g., EDTA or EGTA
• niM e.g., about 1 to 100 mM
• Chelation of divalent cations such as magnesium can inhibit or prevent RNA degradation, as most RNases are magnesium- dependent.
• EDTA does not appear to significantly inhibit Proteinase K activity in the methods of the invention. Further processing - DNA repair
• DNA obtained by the methods disclosed herein can be treated with a translesion DNA polymerase to repair DNA damage (e.g., sustained during storage and removal from paraffin).
• a non-translesion DNA polymerase e.g., containing 3 '-5' exonuclease activity like the Klenow fragment of E. coli DNA polymerase I
• translesion DNA polymerase treatment e.g., containing 3 '-5' exonuclease activity like the Klenow fragment of E. coli DNA polymerase I
• Translesion DNA polymerases function in the replication of damaged DNA.
• Translesion DNA polymerases belong to the "UmuC/DinB/Rad30/Revl" superfamily of DNA polymerases; named for the four prototypic genes that define the subfamilies of the translesion DNA polymerase superfamily.
• Translesion DNA polymerases include E. coli pol IV and pol V, and eukaryotic pol zeta, eta, iota, kappa, and theta.
• Some translesion DNA polymerases are mesophilic (e.g., Pol IV and Pol V from E. coli; Pol kappa from S. cerevisiae, S.
• thermophilic/thermostable e.g., Pol IV from B. stearothermophilus, S. sofataricus.
• FFPE mouse brain and heart tissue samples were processed using the organic solvent citrosol.
• Deparaffinization was performed by adding 1 ml citrosol to the FFPE tissue sections for 30 min with two changes, followed by 100% and 75% ethanol for 30 min with two changes. After a washing step with PBS for 15 min in two changes, 500 ⁇ l of lysis buffer (100 mM NaCl, 10 mM Tris-HCl, pH 8.0; 25 mM EDTA, pH 8.0 and 0.2-0.8 % SDS) was added and samples were incubated at 52 0 C overnight until all tissue fragments were completely dissolved (Shi et al. J. Histochem Cytochem 50:1005-1011, 2002).
• lysis buffer 100 mM NaCl, 10 mM Tris-HCl, pH 8.0; 25 mM EDTA, pH 8.0 and 0.2-0.8 % SDS
• Nucleic acid binding buffer 50 mM Tris-HCl, pH 7.5, 25 mM EDTA, pH 8.0, 4 M guanidine isothiocyanate
• 400 ⁇ l 100 mM Tris-HCl, pH 7.5, 25 mM EDTA, pH 8.0, 4 M guanidine isothiocyanate
• 100% ethanol 800 ⁇ l
• 700 ⁇ l of the solution was loaded onto a GF (F or G) RNA Cartridge column (RNA Cartridge) and centrifuged at maximum speed for 1 minute. The filtrate was discarded. About 700 ⁇ l of the remaining solution was transferred to the same column and the previous step was repeated.
• the column was washed with 500 ⁇ l of wash buffer IT (Invitrogen cat # 12183018) and the filtrate was discarded.
• RNA cartridge column was placed into a new collection tube. The column was washed with 500 ⁇ l of wash buffer II and the filtrate was discarded. The washing step was repeated one more time. The column was then centrifuged for 1 minute to remove any liquid from the cartridge. The RNA cartridge column was placed into a new 2 ml collection tube and 40 ⁇ l RNase-free water or Tris-EDTA (TE) buffer were added. The column was incubated at room temperature for 1 minute, and centrifuged at maximum speed (12,000-14,000 rpm) to elute the RNA, A second elution with 40 ⁇ l water or TE buffer also can be performed.
• TE Tris-EDTA
• RT-PCR was carried out using SuperscriptTM III (Invitrogen cat# 180800511) or ThermoX RT (cat# 11150-025). PCR was carried out using Platinum Taq DNA Polymerase (Invitrogen cat# 10966018).
• RNA yield was either equal to or greater than the chemically processed samples. Extracted total RNA was either untreated or treated with DNase I for comparison. Less gDNA was observed for heat-processed samples than for chemically processed samples.
• RT-PCR reactions using DNase I-digested RNA samples prepared from mouse brain tissue as described above were performed in a volume of 25 ⁇ l for 35 cycles using the following parameters: 94 0 C for 30 sec; 56 0 C for 30 sec and 72 0 C for 40 sec.
• the target gene amplified was mouse ⁇ -actin.
• Aliquots of 8 ⁇ l of PCR products were analyzed by electrophoresis a 2% agarose E-gel (Invitrogen). RT-PCR using heat-processed samples resulted in longer amplification products than RT-PCR using chemically processed samples.
• the Quant-iT RNA Assay Kit (Molecular Probes, Eugene, OR, cat# Q33140) was used to estimate the total RNA yield. Samples were optionally treated with DNaseI by adding 2 ⁇ l DNase I solution (1 unit/ ⁇ l, amplification grade) to 25 ⁇ l of purified RNA and 3 ⁇ l 1OX reaction buffer, then incubating at room temperature for 10 minutes. 2% E-gels (Invitrogen cat# G6018-02) were used to examine the total RNA.
• DNase I-treated RNA was used as template for RT-PCR as described above. PCR cycling conditions were as follows: denaturing at 94°C for 30 sec, annealing at 56°C for 30 seconds, extension at 72°C for 40 sec. A 311 bp fragment of the ⁇ -actin gene was amplified. 5- 7 ⁇ l of each RT-PCR reaction were analyzed by gel electrophoresis.
• Genomic DNA was isolated from 5 pieces of mouse liver FFPE tissue.
• a modified heating protocol for the separation of gDNA from FFPE tissue was followed. Briefly, 300 ⁇ l of melting buffer was added to each tube containing FFPE tissue sections. Two samples were processed for each group.
• the detergents used in the lysis buffer were the same as those shown in Table 1, plus another buffer (buffer 7) was used which contained 1% cetyltrimethylammonium bromide (CTAB). Samples were incubated at 100 0 C for 10 minutes, then centrifuged for 1 min at 12,000 rpm. The aqueous phase under the wax layer was transferred to a new tube, then digested with Proteinase K (20 mg/ml) at 62 0 C for 10 min with occasional mixing.
• CAB cetyltrimethylammonium bromide
• Guanidine HCl 300 ⁇ l of 7.5 M was added to each tube and the samples were heated at 100 0 C for 10 min. Samples were mixed with 200 ⁇ l of 100% ethanol, then applied to a GF RNA cartridge column and washed as described above. Samples were eluted with 40 ⁇ l ddH 2 O. Absorbance values at 260 nm were used to estimate total amounts of nucleic acids isolated. RNase A treatment was performed according to the manufacturer's protocol (Invitrogen). gDNA was examined on a 2% agarose gel and nucleic acid samples before and after RNase A digestion.
• Table 2 shows the nucleic acid concentration of gDNA extracts obtained using buffers 1-7, as determined by the absorbance value at 260 nm (OD260). The OD260 / OD280 ratios confirm that very little protein was present in the samples.
• the column was washed with 500 ⁇ l of washing buffer and the filtrate was discarded. The washing step was repeated once. 100 ⁇ l of Proteinase K solution (2 mg/ml) was added to the column followed by incubation at 62°C for 30 minutes. (For a control group this 2 nd Proteinase K on-column digestion was omitted.) The column was washed with 500 ⁇ l washing buffer and washing was repeated two more times. gDNA was eluted from the column with 40 ⁇ l heated water (72°C) and elution was repeated with 40 ⁇ l heated water. The OD of the nucleic acid sample was confirmed and run on a gel to examine the quality and yield of gDNA.
• Nucleic acid samples isolated with or without 2 nd Proteinase K on-column digestion were compared by digesting genomic DNA with Nsp I restriction enzyme and ligating with Nsp I adaptor (Affymetrix part no. #900766.1). After ligation, PCR was used to amplify the DNA and 5 ⁇ l of PCR product was applied to a 1% agarose gel and subjected to electrophoresis to examine the PCR products.
• gDNA isolated using the 2 nd Proteinase K on- column digestion generated longer PCR products than gDNA isolated without the 2 nd digestion.
• the filtrates were discarded and the mini columns were washed with 500 ⁇ l washing buffer from the Purelink FFPE kit (Invitrogen cat. #K1560-02) and repeated two more times. 10 ⁇ l RNase free water was used to elute the RNA from the mini columns. A second elution was performed using another 10 ⁇ l of RNase free water.
• RNA isolated using the mini column had concentrations between 182- 248 ng/ ⁇ l and the OD260/OD280 ratios (which were 1.89 to 1.91) confirmed that very little protein was present.
• the isolated mouse liver RNA samples were also examined using a 15% TBE/Urea Polyacrylamide Gel. 4 ⁇ l of RNA samples were applied to each well and electrophoresis was performed at constant voltage of 180 volts for 55 minutes. Results indicated that micro RNA isolated using the mini column procedure ranged between 15 to 75 bases long.
• Genomic DNA was purified as in Example 4, above.
• Primer extension reactions were prepared by combining 5 ⁇ l 1Ox Buffer II, 1.25 ⁇ l 10 ⁇ M dNTP, 2.5 ⁇ l 0.25 ⁇ M N6 random primer (mvitrogen Cat. #48190-011), 2.5 ⁇ g gDNA, and water added to a final volume of 48.75 ⁇ l.
• Reaction mixtures were heated to 94°C for two minutes and immediately transferred to ice for one minute.
• 1.25 ⁇ l of enzyme mixture containing Klenow exo- DNA polymerase and Rad 30 DNA polymerase at a 100:1 ratio was added to the reaction tube.
• Reaction mixtures were incubated on ice for 5 minutes, room temperature for 10 minutes, 37°C for one hour, 58°C for 20 minutes and then maintained at 4°C.
• Invitrogen's BioPrime Array CGH genomic labeling system (Invitrogen Cat. # 18095- 011) was used to label the gDNA isolated from FFPE tissues (with or without primer extension using translesion DNA polymerase) according to the manufacturer's kit- recommended protocol. Briefly, 500 ng of gDNA and 30 ⁇ l/ml random primers were incubated at 37°C for two hours with Cy3-dCTP and Cy5-dCTP and DNA was subsequently purified with Purelink Purification Kit (Invitrogen Cat # 18095-013). DNA samples were analyzed using a NanodropTM Spectrophotometer and subjected to electrophoresis on a 6% TBE urea gel.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Genetics & Genomics (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Biotechnology (AREA)
• Biomedical Technology (AREA)
• General Engineering & Computer Science (AREA)
• Analytical Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Microbiology (AREA)
• Biophysics (AREA)
• Physics & Mathematics (AREA)
• Immunology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Crystallography & Structural Chemistry (AREA)
• Plant Pathology (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (2)

Applications Claiming Priority (4)

Publications (2)

Family

ID=37482243

Family Applications (1)

Country Status (4)

Cited By (13)

Families Citing this family (14)

Family Cites Families (17)

• 2006
  • 2006-05-31 US US11/444,171 patent/US9243241B2/en active Active
  • 2006-05-31 JP JP2008514787A patent/JP2008541761A/ja active Pending
  • 2006-05-31 WO PCT/US2006/021011 patent/WO2006130632A2/en not_active Ceased
  • 2006-05-31 EP EP06771657A patent/EP1910389A4/en not_active Withdrawn
  • 2006-10-23 US US11/552,063 patent/US20070128634A1/en not_active Abandoned
• 2016
  • 2016-01-21 US US15/003,179 patent/US20160215281A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events